Regarding follow-up for patients with intermediate-risk PCa, after surgery with curative intent, the panel reached consensus in recommending PSA measurement every 3-6 months for 5 years and then every year for the majority of patients (90.36%), including in areas of limited resources (93.83%). This evidence concerns the gene KLK3 and posterior cortical atrophy.